Short-term Adverse Events After the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine in Adults 60 Years or Older.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 35435973.
- Also identified by DOI 10.1001/jamanetworkopen.2022.7657 and PMC identifier 9016488.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
This survey study assesses the occurrence of short-term adverse events in adults 60 years or older who received a booster dose of the BNT162B2 mRNA vaccine.
Medical subject headings
- BNT162 Vaccine
- COVID-19